Contact
 
News about the Enterprise's Stakeholders.

Report on HIV Prevention Research Funding Says New Investment Critical to Capitalize on HIV Prevention Research Breakthroughs - July 19, 2011

The HIV Vaccines and Microbicides Resource Tracking Working Group released its seventh report on HIV prevention research funding, which states that new investment is critical to capitalizing on HIV prevention breakthroughs. The full report is available here: http://www.hivresourcetracking.org/sites/default/files/RTWG-Capitalizing%20on%20Scientific%20Progress.pdf

AVAC Statement on Results of New PrEP Trials - July 13, 2011

AVAC says results of new PrEP trials provide clear evidence that antiretroviral  drugs for prevention can help end the AIDS epidemic; calls for quick action  to move landmark HIV prevention results toward lifesaving programs.  Read the full statement below. 

IAVI Announces the Appointment of New President & CEO - July 7, 2011

IAVI today announced the appointment of Margaret (Margie) McGlynn as President and Chief Executive Officer. McGlynn, replaces Seth Berkley, IAVI’s Founding President and CEO.  The full announcement is below.

Dr. Anthony Fauci Reflects on 30 Years of HIV/AIDS - May 27, 2011

To commemorate the 30th anniversary of the first reported cases of what is now known as AIDS, Dr. Anthony Fauci, Director, National Institute of Allergy and Infectious Diseases, describes his personal experiences as a physician, leading HIV/AIDS researcher, and scientific administrator during a special lecture and editorial in the Washington Post.

HIV Prevention Trials Network Announce Findings from HPTN 052 - May 12, 2011

The HIV Prevention Trials Network (HPTN) announced findings from HPTN 052, a study to evaluate the immediate versus delayed use of antiretroviral therapy by HIV-infected individuals on transmission to uninfected partners and health of the infected individual. The study showed that initiation of ART by HIV-­‐infected individuals substantially protected their HIV-­uninfected sexual partners from acquiring HIV infection, with a 96 percent reduction in risk of HIV transmission.

Non-Human Primate Studies Reveal Promising Vaccine Approach for HIV - May 11, 2011

A research team led by Dr. Louis Picker at Oregon Health & Science University’s (OHSU) Vaccine and Gene Therapy Institute published findings in Nature that produced a vaccine candidate that programs the immune system of non-human primates to respond more swiftly to the presence of a primate version of HIV than it normally would. Details of this advance are published in the advance online edition of Nature.

Europrise News - April 13, 2011

Europrise distributed its newsletter, see below to access the full newsletter.

Vaccine Research Institute to be Created in France - April 11, 2011

The French National Agency for Research on AIDS and viral hepatitis (ANRS) and the University of Paris Est announce the creation of the Vaccine Research Institute (VRI), whose mission is to  conduct research to develop a vaccine against HIV/AIDS and HCV, following the award of the status of Laboratory of Excellence by the French Prime Minister in March 2011.  Read the full announcement below.

Anthony Fauci on The Colbert Report - April 1, 2011

Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, discusses why HIV is still a problem during his interview on The Colbert Report.  Watch the interview here.

Funding Opportunity: The Canadian HIV Technology Development Program - April 1, 2011

 

On April 01, 2011, small and medium enterprises (SMEs) in Canada were invited to submit project proposals for the new Canadian HIV Technology Development (CHTD) program.  The CHTD falls under the Translating Basic Science into Clinical Trials program area of the Canadian HIV Vaccine Initiative (CHVI), a collaboration between the Government of Canada and the Bill & Melinda Gates Foundation. 

Syndicate content
Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account